Antipsychotic dosing: found in translation

Remington, Gary; Fervaha, Gagan; Foussias, George; Agid, Ofer; Turrone, Peter

doi:10.1503/jpn.130191

Cited by 13 publications

(3 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, such data are not available on all antipsychotics and, for some (e.g., aripiprazole, clozapine, quetiapine), their pharmacology prevents such comparisons. 49 Dosing may also be affected by such factors as stage of illness (e.g., first episode vs. later stages) as well as age (e.g., geriatrics).…”

Section: Recommendations: Pharmacotherapy Of Schizophrenia In Adultsmentioning

confidence: 99%

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

et al. 2017

Self Cite

View full text Add to dashboard Cite

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions:In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.

show abstract

Section: Recommendations: Pharmacotherapy Of Schizophrenia In Adultsmentioning

confidence: 99%

Guidelines for the Pharmacotherapy of Schizophrenia in Adults

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…These studies have compared antipsychotic treatment regimens that achieve sustained brain levels, to regimens achieving regular but extended antipsychotic dosing. As reviewed previously by Rem-ington et al [5], the evidence shows that regular but extended antipsychotic intake can be a safe and effective approach to treat schizophrenia patients. In laboratory animals, regular, extended antipsychotic dosing producing transient D2 occupancy above 65 % is actually more efficacious behaviourally than continuous dosing producing steady-state levels of D2 occupancy above 65 %, while reducing the risk of side effects.…”

Section: Introductionmentioning

confidence: 87%

Continuous versus extended antipsychotic dosing in schizophrenia: Less is more

Servonnet

Uchida

Samaha

2021

Behavioural Brain Research

View full text Add to dashboard Cite

“…3 Extended (alternate day) antipsychotic dosing is one of the strategies for preventing exposure to higher doses of antipsychotics. 4 The peripheral pharmacokinetics of medications remain an important factor when deciding dosing for antipsychotics. 5 But preliminary evidence suggests that central receptor occupancy half-life of a drug may be different from and longer than the peripheral terminal half-life.…”

mentioning

confidence: 99%